NCT05656092

A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of HIP0612 in Patients With Gastric Ulcer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 199 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized, double-blind, active-controlled, phase III study to evaluate the efficacy and safety of HIP0612 in patients with gastric ulcer.

Conditions

• Gastric Ulcer

Interventions

Type	Name	Description
DRUG	HIP0612	Test drug
DRUG	HPP2202	Placebo drug
DRUG	RLD2204	Reference drug
DRUG	HPP2201	Placebo drug

Timeline

• Start date: 2023-03-06
• Primary completion: 2024-12-19
• Completion: 2024-12-19
• First posted: 2022-12-19
• Last updated: 2025-02-19

Locations

1 site across 1 country: South Korea